Top

Current Osteoporosis Reports

Published in:

01-02-2018 | Muscle and Bone (L Bonewald and M Hamrick, Section Editors)

The Role of Bone Secreted Factors in Burn-Induced Muscle Cachexia

Author: Gordon L. Klein

Published in: Current Osteoporosis Reports | Issue 1/2018

Abstract

Purpose of Review

Burn injury results in resorptive bone loss, failure to make new bone, and muscle protein breakdown resulting in cachexia. The purpose of this review is to examine the relationship between bone loss and muscle atrophy in burn injury with a view to understanding the process at work and how it may apply to other conditions that have similar features.

Recent Findings

We present data suggesting that the use of bisphosphonates in the first 10 days following the burn prevents not only the resorptive bone loss but also the muscle wasting. While an extra-osseous effect of bisphosphonates remains possible, existing evidence points to a paracrine effect of bone on maintenance of muscle mass and strength. Proposed paracrine factors produced by bone include prostaglandin E2 and components of the Wnt signaling pathway. TGFβ may be a bone paracrine factor that causes oxidative damage to muscle.

Summary

In the light of the pattern of evidence, burn patients suffer acute resorptive bone loss and muscle wasting. This is likely due to the effects of inflammatory cytokines and endogenous glucocorticoid production in exacerbating oxidative stress. Early use of bisphosphonates can maintain bone mass leading to a paracrine effect of bone in the maintenance of muscle mass, although one cannot completely discount a direct effect of bisphosphonate on muscle. Because investigators report this relationship in a variety of conditions in addition to burns, physicians should seriously consider the early use of bisphosphonates to maintain bone and muscle mass in a variety of neuromuscular and skeletal diseases.

Klein GL, Herndon DN, Goodman WG, Langman CB, Phillips WA, Dickson IR, et al. Histomorphometric and biochemical characterization of bone following acute severe burns in children. Bone. 1995;17(5):455–60. https://doi.org/10.1016/8756-3282(95)00279-1.CrossRefPubMed

Hart DW, Wolf SE, Mlcak R, Chinkes DL, Ramzi PI, Obeng MK, et al. Persistence of muscle catabolism after severe burn. Surgery. 2000;128(2):312–9. https://doi.org/10.1067/msy.2000.108059.CrossRefPubMed

Klein GL, Xie Y, Qin YX, Lin L, Hu M, Enkhbaatar P, et al. Preliminary evidence of acute bone resorption in a sheep model of acute burn injury: an observational study. J Bone Miner Metab. 2014;32(2):136–41. https://doi.org/10.1007/s00774-013-0483-4.CrossRefPubMed

Klein GL, Herndon DN, Langman CB, Rutan TC, Young WE, Pembleton G, et al. Long-term reduction in bone mass after severe burn injury in children. J Pediatr. 1995;126(2):252–6. https://doi.org/10.1016/S0022-3476(95)70553-8.CrossRefPubMed

Przkora R, Herndon DN, Sherrard DJ, Chinkes DL, Klein GL. Pamidronate preserves bone mass for at least two years following administration for pediatric burn injury. Bone. 2007;41(2):297–302. https://doi.org/10.1016/j.bone.2007.04.195.CrossRefPubMedPubMedCentral

Mayes T, Gottschlich MM, Khoury J, Kagan RJ. Investigation of bone health subsequent to vitamin D supplementation in children following burn injury. Nutr Clin Pract. 2015;30(6):830–7. https://doi.org/10.1177/0884533615587720.CrossRefPubMed

Muschitz GK, Schwabeggar E, Fochtmann A, Baierl A, Kocjian R, Haschka J, et al. Long-term effects of severe burn injury on bone turnover and microarchitecture. J Bone Miner Res. 2017;32(12):2381–93. https://doi.org/10.1002/jbmr.3211 epublished before print.

• Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011;286:44326–35. https://doi.org/10.1074/jbc.M111.283481. This paper implicates both glucocorticoids and pro-inflammatory cytokines as agents of oxidative stress. CrossRefPubMedPubMedCentral

Qin W, Pan J, Qin Y, Lee DN, Bauman WA, Cardozo C. Identification of glucocorticoid response element in the mouse FOXO1 promoter. Biochem Biophys Res Commun. 2014;450(2):979–83. https://doi.org/10.1016/j.bbrc.2014.06.080.CrossRefPubMed

10.

Smith IJ, Alamdari N, O’Neal P, Gonnella P, Aversa Z, Hasselgren PO. Sepsis increases the expression and activity of forkhead box O in skeletal muscle by a glucocorticoid dependent mechanism. Int J Biochem Cell Biol. 2010;42(5):701–11. https://doi.org/10.1016/j.biocel.2010.01.006.CrossRefPubMedPubMedCentral

11.

Iyer S, Ambrogini E, Bartell SM, Han L, Roberson PK, deCabo R, et al. FOXOs attenuate bone formation by preventing Wnt signaling. J Clin Invest. 2013;123(8):3409–19. https://doi.org/10.1172/JCI168049.CrossRefPubMedPubMedCentral

12.

Bartell SM, Kim HN, Ambrogini E, Han L, Iyer S, Serra Ucer S, et al. FOXO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014;5:3773. https://doi.org/10.1038/ncomms4773.CrossRefPubMedPubMedCentral

13.

Fairfield H, Rosen CJ, Reagan MR. Connecting bone and fat: the potential role of sclerostin. Curr Mol Biol Rep. 2017;3(2):114–21. https://doi.org/10.1007/s40610-017-0057-7.CrossRefPubMed

14.

Hart DW, Herndon DN, Klein G, Lee SB, Celis M, Mohan S, et al. Attenuation of post-traumatic muscle catabolism and osteopenia by long-term growth hormone therapy. Ann Surg. 2001;233(6):827–34. https://doi.org/10.1097/00000658-200106000-00013.CrossRefPubMedPubMedCentral

15.

Klein GL, Wolf SE, Langman CB, Rosen CJ, Mohan S, Keenan BS, et al. Effects of therapy with recombinant human growth hormone on insulin-like growth factor system components and serum levels of biochemical markers of bone formation in children after severe burn injury. J Clin Endocrinol Metab. 1998;83(1):21–4. https://doi.org/10.1210/jcem.83.1.4518.PubMed

16.

• Branski LK, Herndon DN, Barrow RE, Kulp G, Klein GL, Suman OE, et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann Surg. 2009;250:514–23. https://doi.org/10.1097/SLA.0b013e3181b8f9ca. This paper separates the direct effects of recombinant human growth hormone on lean body mass and the direct effect of high doses of growth hormone on bone resorption, effectively separating the direct effect of growth hormone on muscle from the anabolic effect of growth hormone on bone. PubMedPubMedCentral

17.

Murphy KD, Thomas S, Mlcak RP, Chinkes DL, Klein GL, Herndon DN. Effects of long-term oxandrolone in severely burned children. Surgery. 2004;136(2):219–24. https://doi.org/10.1016/j.surg.2004.04.022.CrossRefPubMed

18.

Porro LJ, Herndon DN, Rodriguez NA, Jennings K, Klein GL, Mlcak R, et al. Five year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. J Am Coll Surg. 2012;214(4):489–502. https://doi.org/10.1016/j.jamcollsurg.2011.12.038.CrossRefPubMedPubMedCentral

19.

Reeves PT, Herndon DN, Tanksley JD, Jennings K, Klein GL, Mlcak R, et al. Five year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial. Shock. 2016;45(4):367–74. https://doi.org/10.1097/SHK.0000000000000517.CrossRefPubMedPubMedCentral

20.

Klein GL, Wimalawansa SJ, Kulkarni G, Sherrard DJ, Sanford AP, Herndon DN. The efficacy of acute administration of pamidronate on the conservation of bone mass following acute severe burn injury in children: a double-blind randomized controlled study. Osteoporos Int. 2005;16(6):631–5. https://doi.org/10.1007/s00198-004-1731-1.CrossRefPubMed

21.

• Borsheim E, Herndon DN, Hawkins HK, Suman OE, Cotter M, Klein GL. Pamidronate attenuates muscle protein loss following pediatric burn injury. J Bone Miner Res. 2014;29:1369–72. https://doi.org/10.1002/jbmr.2162. This was the first paper to demonstrate an effect of a primarily bone-active drug on muscle protein kinetics in vivo. The implication is that either bone structure and function is maintained during burn injury or that the drug is also taken up by muscle and is able to function within muscle. CrossRefPubMedPubMedCentral

22.

Klein GL. Disruption of bone and skeletal muscle in severe burns. Bone Res. 2015;3:15002. https://doi.org/10.1038/boneres.2015.2.

23.

Lang CH, Silvis C, Nystrom G, Frost RA. Regulation of myostatin by glucocorticoids after thermal injury. FASEB J. 2001;15(10):1807–9.CrossRefPubMed

24.

Qin Y, Peng Y, Zhao W, Pan J, Ksiezak-Reding H, Cardozo C, et al. Myostatin inhibits osteoblastic differentiation by suppressing osteocyte derived exosomal micro RNA-218. A novel mechanism in muscle-bone communication. J Biol Chem. 2017;292(26):11021–33. https://doi.org/10.1074/jbc.M116.770941.CrossRefPubMed

25.

Klein GL, Nicolai M, Langman CB, Cuneo BF, Sailer DE, Herndon DN. Dysregulation of calcium homeostasis after severe burn injury in children: possible role of magnesium depletion. J Pediatr. 1997;131(2):246–51. https://doi.org/10.1016/S0022-3476(97)70161-6.CrossRefPubMed

26.

Murphey ED, Chattopadhyay N, Bai M, Kifor O, Harper D, Traber DL, et al. Up-regulation of the parathyroid calcium-sensing receptor after burn injury in sheep: a potential contributory factor to post-burn hypocalcemia. Crit Care Med. 2000;28(12):3885–90. https://doi.org/10.1097/00003246-200012000-00024.CrossRefPubMed

27.

Griffin JF 4th, Young BD, Fosgate GT, Walker MA, Watkins JP. Focal skeletal muscle uptake of 99m Technetium-hydroxymethylene diphosphonate following peroneal nerve blocks in horses. Vet Radiol Ultrasound. 2010;51:338–43.CrossRefPubMed

28.

Arend SM, Pawels EK, Arndt JW, Meinders AE. Extraosseous localization of 99mTc-labeled bone-seeking tracers in bone scintigraphy. Neth J Med. 1994;45(4):177–91.PubMed

29.

• Mo C, Romero-Suarez S, Bonewald L, Johnson M, Brotto M. Prostaglandin E2: clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation. Recent Pat Biotechnol. 2012;6:223–9. This paper shows in vitro that prostaglandin E2 but not sclerostin or monocyte chemotactic protein (MCP)-3 increased C2C12 myoblast differentiation and changes in intracellular calcium signaling. CrossRefPubMedPubMedCentral

30.

• Huang J, Romero-Suarez S, Lara N, Mo C, Kaja S, Brotto L, et al. Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt/β catenin pathway. JBMR Plus. 2018; https://doi.org/10.1002/jbm4.10015. This paper expands the findings of Mo et al (29) to show that Wnt 3a and osteocyte conditioned media increased C2C12 myoblast differentiation, which was inhibited by sclerostin. It also demonstrates up-regulation of markers of myogenesis and two Wnt/β catenin downstream genes and enhancement of muscle contraction.

31.

Klein GL, Herndon DN, Le PT, Andersen CR, Benjamin D, Rosen CJ. The effect of burn on serum concentrations of sclerostin and FGF23. Burns. 2015;41(7):1532–5. https://doi.org/10.1016/j.burns.2015.04.001.CrossRefPubMedPubMedCentral

32.

• Watanabe R, Fujita N, Takeda S, Sato Y, Kobayashi T, Morita M, et al. Ibandronate concurrently blocks immobilization-induced bone and muscle atrophy. Biochem Biophys Res Commun. 2016;480:662–8. https://doi.org/10.1016/j.bbrc.2016.10.112. This paper links the bisphosphonate ibandronate with the blockage of bone and muscle atrophy seen with immobilization. CrossRefPubMed

33.

• Regan JN, Trivedi T, Guise TA, Waning DL. The role of TGFβ in bone-muscle crosstalk. Curr Osteoporos Rep. 2017;15:18–23. https://doi.org/10.1007/s11914-017-0344-5. This paper describes the findings of damage that breast cancer metastases do to bone, the release of TGFβ from the bone, its transit to muscle and damage to the ryanodine receptor causing muscle calcium leakage and the abolition of this response by the bisphosphonates. CrossRefPubMed

34.

Yoon SH, Sugamori KS, Grynpas MD, Mitchell J. Positive bisphosphonate effects on bone and muscle in a mouse model of Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(1):73–84. https://doi.org/10.1016/j.nmd.2015.09.015.CrossRefPubMed

35.

Mera P, Laue K, Wei J, Berger JM, Karsenty G. Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol Metab. 2016;5(10):1042–7. https://doi.org/10.1016/j.molmet.2016.07.002. eCollection 2016 Oct.

36.

Mera P, Laue K, Ferron M, Confavreux C, Wei J, Galan-Diez M, et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 2016;23(6):1078–92. https://doi.org/10.1016/j/cmet.2016.05.004. CrossRefPubMedPubMedCentral

Title: The Role of Bone Secreted Factors in Burn-Induced Muscle Cachexia
Author: Gordon L. Klein
Publication date: 01-02-2018
Publisher: Springer US
Published in: Current Osteoporosis Reports / Issue 1/2018
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-018-0416-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Role of Bone Secreted Factors in Burn-Induced Muscle Cachexia

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Diabetes and Abdominal Aortic Calcification—a Systematic Review

Regulation of Bone Metabolism by microRNAs

Exosomes in Extracellular Matrix Bone Biology

Linking the Gut Microbiota to Bone Health in Anorexia Nervosa

Genetics of Osteopetrosis

Solute Transport in the Bone Lacunar-Canalicular System (LCS)